Thermo Fisher Scientific (TMO) Shares Bought by Lyell Wealth Management LP

Lyell Wealth Management LP raised its position in Thermo Fisher Scientific (NYSE:TMO) by 3.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 17,227 shares of the medical research company’s stock after acquiring an additional 640 shares during the quarter. Lyell Wealth Management LP’s holdings in Thermo Fisher Scientific were worth $3,560,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of TMO. Viking Global Investors LP acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $154,660,000. Cornerstone Investment Partners LLC boosted its holdings in Thermo Fisher Scientific by 89.8% in the 4th quarter. Cornerstone Investment Partners LLC now owns 802,374 shares of the medical research company’s stock worth $152,355,000 after buying an additional 379,703 shares during the last quarter. Longview Partners Guernsey LTD boosted its holdings in Thermo Fisher Scientific by 6.8% in the 4th quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock worth $926,024,000 after buying an additional 311,977 shares during the last quarter. Elkfork Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $46,978,000. Finally, Schroder Investment Management Group boosted its holdings in shares of Thermo Fisher Scientific by 28.1% during the 4th quarter. Schroder Investment Management Group now owns 1,103,685 shares of the medical research company’s stock worth $209,568,000 after purchasing an additional 242,062 shares during the last quarter. Institutional investors own 86.52% of the company’s stock.

Several research analysts have recently weighed in on the company. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, March 26th. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Barclays boosted their target price on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Finally, Bank of America boosted their target price on Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, February 1st. One analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus target price of $222.50.



TMO stock opened at $216.55 on Monday. The company has a market cap of $87.12 billion, a PE ratio of 21.87, a PEG ratio of 1.59 and a beta of 1.14. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.36. Thermo Fisher Scientific has a one year low of $170.07 and a one year high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 25th. The medical research company reported $2.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.08. The firm had revenue of $5.85 billion for the quarter, compared to analyst estimates of $5.62 billion. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The business’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.08 EPS. analysts forecast that Thermo Fisher Scientific will post 10.9 earnings per share for the current year.

In other news, Director William G. Parrett sold 1,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $211.43, for a total transaction of $211,430.00. Following the sale, the director now owns 11,660 shares of the company’s stock, valued at approximately $2,465,273.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $204.60, for a total transaction of $511,500.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,500 shares of company stock worth $9,339,130. Corporate insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply